JP2019516392A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516392A5
JP2019516392A5 JP2018567013A JP2018567013A JP2019516392A5 JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5 JP 2018567013 A JP2018567013 A JP 2018567013A JP 2018567013 A JP2018567013 A JP 2018567013A JP 2019516392 A5 JP2019516392 A5 JP 2019516392A5
Authority
JP
Japan
Prior art keywords
seq
constant domain
ilt7
item
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567013A
Other languages
English (en)
Japanese (ja)
Other versions
JP6979976B2 (ja
JP2019516392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021616 external-priority patent/WO2017156298A1/en
Publication of JP2019516392A publication Critical patent/JP2019516392A/ja
Publication of JP2019516392A5 publication Critical patent/JP2019516392A5/ja
Priority to JP2021186637A priority Critical patent/JP7354212B2/ja
Application granted granted Critical
Publication of JP6979976B2 publication Critical patent/JP6979976B2/ja
Priority to JP2023151943A priority patent/JP7700190B2/ja
Priority to JP2025101902A priority patent/JP2025134836A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567013A 2016-03-10 2017-03-09 Ilt7結合分子及びその使用方法 Active JP6979976B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021186637A JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306125P 2016-03-10 2016-03-10
US62/306,125 2016-03-10
PCT/US2017/021616 WO2017156298A1 (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021186637A Division JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019516392A JP2019516392A (ja) 2019-06-20
JP2019516392A5 true JP2019516392A5 (enExample) 2020-04-16
JP6979976B2 JP6979976B2 (ja) 2021-12-15

Family

ID=59790876

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018567013A Active JP6979976B2 (ja) 2016-03-10 2017-03-09 Ilt7結合分子及びその使用方法
JP2021186637A Active JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A Active JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A Pending JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021186637A Active JP7354212B2 (ja) 2016-03-10 2021-11-16 Ilt7結合分子及びその使用方法
JP2023151943A Active JP7700190B2 (ja) 2016-03-10 2023-09-20 Ilt7結合分子及びその使用方法
JP2025101902A Pending JP2025134836A (ja) 2016-03-10 2025-06-18 Ilt7結合分子及びその使用方法

Country Status (16)

Country Link
US (3) US11072652B2 (enExample)
EP (1) EP3426298A4 (enExample)
JP (4) JP6979976B2 (enExample)
KR (5) KR102603010B1 (enExample)
CN (2) CN109414499B (enExample)
AR (2) AR109450A1 (enExample)
AU (2) AU2017231833B2 (enExample)
CA (1) CA3017197A1 (enExample)
IL (2) IL321334A (enExample)
MX (2) MX2018010771A (enExample)
RU (1) RU2756109C2 (enExample)
SG (2) SG11201807523PA (enExample)
TW (1) TWI755380B (enExample)
UA (1) UA127731C2 (enExample)
WO (1) WO2017156298A1 (enExample)
ZA (1) ZA201806597B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
US11787858B2 (en) * 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
MX2021012726A (es) * 2019-04-19 2021-11-17 Allogene Therapeutics Inc Anticuerpos contra receptores de antigenos quimericos derivados de 4g7.
WO2021113702A1 (en) * 2019-12-06 2021-06-10 Viela Bio, Inc. Methods of treatment using ilt7 binding proteins
EP4076503A4 (en) * 2019-12-20 2024-04-03 MedImmune, LLC COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN 3
WO2021203013A2 (en) * 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
AU2022270101A1 (en) 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2025526370A (ja) 2022-07-27 2025-08-13 ビエラ バイオ インコーポレイテッド 免疫グロブリン様転写物7(ilt7)結合タンパク質を含む製剤
EP4634225A1 (en) 2022-12-12 2025-10-22 Viela Bio, Inc. Anti-ilt7 binding agents for the treatment and prevention of myositis
EP4680344A1 (en) * 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096948A (en) 1935-12-20 1937-10-26 Anchor Steel & Conveyor Co Conveyer system
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440354A1 (de) 1994-11-11 1996-05-15 Hoechst Schering Agrevo Gmbh Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006513462A (ja) 2002-03-20 2006-04-20 カタリナ マーケティング インターナショナル,インク. 予測された行動に基づくターゲット・インセンティブ
NZ536475A (en) 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CN100558895C (zh) 2003-07-18 2009-11-11 持田制药株式会社 抗血小板膜糖蛋白vi单克隆抗体
US9208495B2 (en) 2003-10-06 2015-12-08 Yellowpages.Com Llc Methods and apparatuses for advertisement presentation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートBaylor Research Institute 抗インターフェロンアルファモノクローナル抗体及び使用方法
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
HUE039865T2 (hu) 2005-12-20 2019-02-28 Sbi Biotech Co Ltd Anti-ILT7 antitest
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
US8071323B2 (en) 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
EP2589654A1 (en) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US7781306B2 (en) 2007-06-20 2010-08-24 Semiconductor Energy Laboratory Co., Ltd. Semiconductor substrate and method for manufacturing the same
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2010065536A2 (en) 2008-12-01 2010-06-10 The Board Of Regents Of The University Of Texas System Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
AU2010289383B2 (en) 2009-09-03 2015-04-16 Medimmune, Llc Type 1 interferon diagnostic
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
JP6211513B2 (ja) 2011-04-26 2017-10-11 ジェネンテック, インコーポレイテッド 自己免疫疾患の治療のための組成物及び方法
CA2833917C (en) 2011-04-28 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Identification of polynucleotides associated with a sample.
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
CN104284903B (zh) * 2012-01-31 2020-10-09 Sbi生物技术有限公司 抗磷脂酶d4抗体
US8605807B1 (en) 2012-05-22 2013-12-10 Nigel Iain Stuart Macrae Communicating distinct data over a single frequency using multiple linear polarized signals
KR102467714B1 (ko) * 2012-11-08 2022-11-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
US9114438B2 (en) 2013-05-21 2015-08-25 Applied Materials, Inc. Copper residue chamber clean
EP3185897A4 (en) 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
JP6979976B2 (ja) * 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
WO2021113702A1 (en) 2019-12-06 2021-06-10 Viela Bio, Inc. Methods of treatment using ilt7 binding proteins
AU2022270101A1 (en) 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins

Similar Documents

Publication Publication Date Title
CN112135626A (zh) 抗tigit抗体及其用途
CN110536903A (zh) 抗ox40抗体及其用途
WO2016000619A1 (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
JP2020508655A5 (enExample)
JP2022533538A5 (enExample)
JP2014509861A5 (enExample)
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
CN113874400A (zh) 抗Vβ17/抗CD123双特异性抗体
JP2012526558A5 (enExample)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2018135550A (ru) Связывающие ilt7 молекулы и способы их применения
JP2023519962A5 (enExample)
JP2024540148A5 (enExample)
CN109721656B (zh) 靶向rankl的治疗性抗体
RU2019135404A (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JP2024516098A5 (enExample)
JP2019528046A5 (enExample)
RU2019103991A (ru) Анти-il-22r-антитела
CN121851171A (zh) St2抗原结合蛋白
JP2023532248A5 (enExample)
JP2024523514A5 (enExample)
JP2025508835A5 (enExample)
RU2020128108A (ru) Антитело против cd25 для опухоль-специфической клеточной деплеции
JP2021513357A5 (enExample)